Eidos Therapeutics Inc
(EIDX)
[[ item.lastPrice ]]
[[ item.priceChange ]]
([[ item.percentChange ]])
[[ item.tradeTime ]]
[NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]]
[[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]]
by (Cboe BZX)
[[ item.lastPrice ]]
[[ item.priceChange ]]
([[ item.percentChange ]])
[[ item.tradeTime ]]
[NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]]
[[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]]
[[ item.lastPriceExt ]]
[[ item.priceChangeExt ]]
([[ item.percentChangeExt ]])
[[ item.tradeTimeExt ]]
Fiscal Year End Date: 12/31
(Values in U.S. thousands)
| 09-2020 | 06-2020 | 03-2020 | 12-2019 | 09-2019 | |
| Cash Flows From Operating Activities | |||||
| Net Income | -81,849 | -51,673 | -22,824 | -37,835 | -18,855 |
| Depreciation Amortization | 877 | 593 | 231 | 185 | 53 |
| Accounts payable and accrued liabilities | -770 | -911 | 821 | 1,195 | 1,611 |
| Other Working Capital | 4,182 | 5,541 | 1,851 | 622 | -60 |
| Other Operating Activity | 8,993 | 5,517 | 1,044 | 4,185 | 2,108 |
| Operating Cash Flow | $-68,567 | $-40,933 | $-18,877 | $-31,648 | $-15,143 |
| Cash Flows From Investing Activities | |||||
| PPE Investments | -350 | -243 | -51 | -227 | -147 |
| Investing Cash Flow | $-350 | $-243 | $-51 | $-227 | $-147 |
| Cash Flows From Financing Activities | |||||
| Debt Issued | N/A | N/A | N/A | 17,500 | N/A |
| Common Stock Issued | 25,087 | 24,840 | 24,286 | 48,733 | 23,965 |
| Other Financing Activity | 0 | 0 | 0 | -348 | 0 |
| Financing Cash Flow | $25,087 | $24,840 | $24,286 | $65,885 | $23,965 |
| Beginning Cash Position | 191,157 | 191,157 | 191,157 | 157,147 | 157,147 |
| End Cash Position | 147,327 | 174,821 | 196,515 | 191,157 | 165,822 |
| Net Cash Flow | $-43,830 | $-16,336 | $5,358 | $34,010 | $8,675 |
| Free Cash Flow | |||||
| Operating Cash Flow | -68,567 | -40,933 | -18,877 | -31,648 | -15,143 |
| Capital Expenditure | -350 | -243 | -51 | -227 | -147 |
| Free Cash Flow | -68,917 | -41,176 | -18,928 | -31,875 | -15,290 |